|
|
| Model Number |
70600 |
| Medical Device Problem Code |
Adverse Event Without Identified Device or Use Problem (2993)
|
| Health Effect - Clinical Code |
Low Oxygen Saturation (2477)
|
| Date of Event |
07/01/2012
|
|
Type of Reportable Event
|
Serious Injury
|
|
Additional Manufacturer Narrative
|
|
Lot number and expiry information are not available at this time.Article citation: allen es, stroncek df, ren j, et al.Autologous lymphapheresis for the production of chimeric antigen receptor t cells.Transfusion 2017;57:1133-41.Article may be obtained online: https://www.Ncbi.Nlm.Nih.Gov/pmc/articles/pmc5398918/ investigation is in process.A follow-up report will be provided.
|
| |
|
Event or Problem Description
|
|
Allen, et.Al.(2017) reported their experience at the national institutes of health (nih) with apheresis for car t manufacturing in pediatric and young adult patients aged 4 to 30 years with acute lymphoblastic leukemia (all) and solid tumors.Of the 71 collections, two (3%) yielded fewer than the minimum of 0.6 × 10^9 cd3+ cells requested for manufacturing.An additional 14 collections (20%) achieved the minimum, but not the target of 2 × 10^9 cd3+ cells.The cobe spectra instrument was used for these collections.71 mnc collections performed on cobe spectra on patients participating in 3 car t cell clinical trials.Collections occurred between july 1, 2012 and january 31, 2016.One patient experienced oxygen desaturation to 87%, which was resolved with supplemental oxygen.Patient information is not available at this time.The disposable set is not available for return because it was discarded by the customer.
|
| |
|
Event or Problem Description
|
|
This was a retrospective review of clinical trials into the production of car t cells from mnc collections performed on cobe spectra between july 1, 2012 and january 31, 2016, involving 71 pediatric and young adult patients aged 4 to 30 years.The average patient age was 14.9 years old.The majority were male and the average patient weight 48.0 kg.58 patients were diagnosed with all and 13 patients with "solid tumor" (includes: osteosarcoma, neuroblastoma, diffuse large b cell lymphoma).A request for specific patient information is not feasible.
|
| |
|
Additional Manufacturer Narrative
|
|
Investigation: one patient experienced oxygen desaturation to 87%, resolved with supplemental oxygen.No further details on extent of medical inter vention are known.According to therapeutic apheresis: a physician's handbook, adverse events occur during therapeutic procedures with a frequency of 4.8%.Some of the most common reactions include fever, urticaria, hypocalcemic symptoms, pruritus, dyspnea, tachycardia, and mild hypotension.Vasovagal incidents occur around 0.5% of procedures.The reactions generally manifest as pallor and diaphoresis.In a full blown attack, the reaction progresses from pallor and sweating to pulse slowing and blood pressure decreasing.More severe vasovagal reactions may include nausea, vomiting, and/or convulsions dhr details: since this was a retrospective review of clinical trials into the production of car t cells from mnc collections performed on cobe spectra between july 1, 2012 and january 31, 2016, the lot numbers are unknown; therefore, a dhr search could not be conducted for the reported incident.All lots must meet acceptance criteria for release.Root cause: cause for the patient's oxygen desaturation could not be determined but may be due to patient disease state and/or patient sensitivity to the procedure.
|
| |
|
Search Alerts/Recalls
|
|
|